{"id":763,"date":"2017-02-14T08:52:56","date_gmt":"2017-02-14T07:52:56","guid":{"rendered":"http:\/\/intervacc.se\/en\/?page_id=763"},"modified":"2020-04-14T21:06:25","modified_gmt":"2020-04-14T19:06:25","slug":"recombinant-technology","status":"publish","type":"page","link":"https:\/\/intervacc.se\/en\/research\/recombinant-technology\/","title":{"rendered":"Technology platform"},"content":{"rendered":"
\n

Intervacc\u00b4s novel vaccines are based on research carried out at the Karolinska Institute and the Swedish University of Agricultural Sciences. Below follows a brief summary of the technology with adhesins used as vaccine components, a technology which forms a basis for Intervacc\u00b4s development program.<\/p>\n<\/div>\n

Mechanism of\u00a0protection with bacterial adhesins<\/h3>\n

In order for a bacterium to be infectious, it must be able to adhere to a tissue surface.\u00a0This is done by surface-localised bacterial proteins, called adhesins, which have a specific binding affinity to e.g.\u00a0collagen, fibrin, fibronectin and numerous other tissue structures.<\/p>\n

The principle of Intervacc\u2019s vaccine development is to identify such surface-localised bacterial adhesins and to produce these in a large scale by recombinant technology.\u00a0When the adhesins are used as vaccine components, specific antibodies are formed that have two functions:<\/p>\n

1) bind to the adhesins and block the bacterial adhesion to the tissue thereby\u00a0impeding the infection process.<\/p>\n

\"\"<\/a><\/p>\n

2) bind to the adhesins and thereby provide a signal to the white blood cells to internalise and kill the bacteria.<\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n


Intervacc’s vaccine development<\/h3>\n

The proteins that make up the adhesins have been\u00a0identified by bioinformatic analysis of DNA sequences from\u00a0Streptococcus equi<\/em>\u00a0and can be compared with previously known virulence factors from e.g.\u00a0Streptococcus pyogenes,<\/em>\u00a0a human pathogen with similar pathogenesis as strangles.\u00a0Other proteins have been identified, whose effect is of importance to the infection process, for instance\u00a0by impairing the horse’s immune system.\u00a0Antibodies against these have a neutralising effect and deprive the bacteria of this “weapon” and thereby attenuating the infectious ability of the bacteria.<\/p>\n

The effect of a vaccine increases substantially if multiple components are included in the vaccine.\u00a0In order to reduce production costs Intervacc have fused the genes coding for various proteins so that multiple proteins are included in the same polypeptide.\u00a0For example Strangvac\u00ae<\/sup> contains three polypeptides that are derived from eight different proteins.<\/p>\n

The same approach to vaccine development has been selected for vaccine candidates against\u00a0Streptococcus suis<\/em>\u00a0and against\u00a0Staphylococcus aureus.<\/em><\/p>\n

Strains of\u00a0Streptococcus equi <\/em>isolated from strangles outbreaks from different parts of the world are very similar to each other, which means that only one version of the vaccine is necessary to provide global coverage.<\/p>\n

Conventional vaccines against bacterial infections generally consist of live attenuated or killed bacteria or specific components, such as capsular polysaccharides and toxoids.\u00a0When attenuated bacteria are used as vaccines a sub-clinical infection is induced, often with mild or no symptoms, but antibodies are formed which have a protective ability.\u00a0The risk is, however, that the sub-clinical infection of the vaccine strain develops into a more serious infection.\u00a0When using bacteria-containing vaccines against strangles, there have been reports on horses that have suffered from strangles infection instead of being protected from the disease.\u00a0These vaccines against strangles are used only to a small degree.\u00a0 Intervacc have therefore chosen not to develop these types of vaccines.<\/p>\n

To summarise, Intervacc possess the technology, expertise and strategic collaborations to take a project from the research stage to the finished product.<\/p>\n","protected":false},"excerpt":{"rendered":"

Intervacc\u00b4s novel vaccines are based on research carried out at the Karolinska Institute and the Swedish University of Agricultural Sciences. Below follows a brief summary of the technology with adhesins used as vaccine components, a technology which forms a basis for Intervacc\u00b4s development program. Mechanism of\u00a0protection with bacterial adhesins In order for a bacterium to […]<\/p>\n","protected":false},"author":1,"featured_media":1387,"parent":754,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false},"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/763"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=763"}],"version-history":[{"count":17,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/763\/revisions"}],"predecessor-version":[{"id":220626,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/763\/revisions\/220626"}],"up":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media\/1387"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}